<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875548</url>
  </required_header>
  <id_info>
    <org_study_id>EZH-501</org_study_id>
    <nct_id>NCT02875548</nct_id>
  </id_info>
  <brief_title>Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study</brief_title>
  <acronym>TRuST</acronym>
  <official_title>Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epizyme, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This rollover study will provide continuing availability to tazemetostat as a single agent to&#xD;
      subjects who have completed their participation in an antecedent tazemetostat study (either&#xD;
      with monotherapy or combination therapy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, multicenter, global study will provide continuing access to tazemetostat&#xD;
      therapy for subjects who have completed their participation in a prior tazemetostat study&#xD;
      (either with monotherapy or combination therapy) without unacceptable toxicity, have not had&#xD;
      evidence of tumor progression as defined by disease-appropriate standard criteria, and&#xD;
      continue to receive clinical benefit from the therapy.&#xD;
&#xD;
      Subjects will receive tazemetostat as dictated in their antecedent study. Visits will be&#xD;
      conducted per Standard of Care (SoC) as appropriate in each country and as determined by the&#xD;
      Investigator. Subjects will be followed for long-term safety in addition to time to treatment&#xD;
      failure (TTF) and overall survival (OS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The long-term safety profile of tazemetostat measured by number of AEs and duration of exposure to tazemetostat</measure>
    <time_frame>From the date of first dose to discontinuation for any reason, including disease progression, withdrawal of consent or death, up to 7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The overall survival (OS) of subjects receiving tazemetostat</measure>
    <time_frame>From the date of the first dose of tazemetostat to the date of death due to any cause, up to 7 years</time_frame>
    <description>OS, defined as the interval of time between the date of the first dose of tazemetostat and the date of death due to any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The time to treatment failure (TTF) in subjects receiving tazemetostat</measure>
    <time_frame>The time from date of first dose of study treatment to treatment discontinuation for any reason including disease progression, treatment toxicity, subject preference or death, up to 7 years</time_frame>
    <description>TTF, defined as the time from date of first dose of study drug to treatment discontinuation for any reason, including disease progression, treatment toxicity, subject preference, or death</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <condition>Follicular Lymphoma (FL)</condition>
  <condition>Synovial Sarcoma</condition>
  <condition>Epitheliod Sarcoma (ES)</condition>
  <condition>Mesothelioma</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Renal Medullary Carcinoma</condition>
  <condition>Non-Hodgkin Lymphoma (NHL)</condition>
  <arm_group>
    <arm_group_label>Open-label Tazemetostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol. For subjects on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.</description>
    <arm_group_label>Open-label Tazemetostat</arm_group_label>
    <other_name>EPZ-6438</other_name>
    <other_name>E7438</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must meet ALL criteria to be eligible for enrollment in this study.&#xD;
&#xD;
          2. Has demonstrated and continues to demonstrate clinical benefit from treatment with&#xD;
             tazemetostat.&#xD;
&#xD;
          3. Is currently receiving tazemetostat as either monotherapy or in combination with other&#xD;
             approved drug(s) or investigational agent(s) on an Epizyme-sponsored clinical trial or&#xD;
             any other clinical trial being conducted with tazemetostat that is not sponsored by&#xD;
             Epizyme (including but not limited to, investigator-initiated trials). For subjects on&#xD;
             combination therapy, treatment with other therapeutic(s) must have been completed in&#xD;
             the antecedent study or will be provided by a source other than Epizyme if combination&#xD;
             therapeutics are continued in this study.&#xD;
&#xD;
          4. Has voluntarily provided signed written informed consent and demonstrated willingness&#xD;
             and ability to comply with all aspects of the protocol.&#xD;
&#xD;
          5. Has a life expectancy of ≥3 months.&#xD;
&#xD;
          6. Has adequate hematologic, (bone marrow [BM] and coagulation factors), renal, and&#xD;
             hepatic function. Subject must remain eligible for continued treatment with&#xD;
             tazemetostat according to the eligibility and treatment criteria from the antecedent&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting ANY of the following criteria must NOT be enrolled in this study:&#xD;
&#xD;
          1. Has had an interruption of tazemetostat dosing of &gt;14 days from the antecedent&#xD;
             clinical study to starting the rollover study unless approved by the Medical Monitor.&#xD;
&#xD;
          2. Has another malignancy other than the one for which they are receiving tazemetostat.&#xD;
&#xD;
             • Exception: Subject who has been disease-free of a prior malignancy for 5 years or&#xD;
             subject with a history of a completely resected non-melanoma skin cancer or&#xD;
             successfully treated in situ carcinoma is eligible.&#xD;
&#xD;
          3. Has thrombocytopenia, neutropenia, or anemia of Grade ≥3 (per CTCAE v5 criteria) or&#xD;
             any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS).&#xD;
&#xD;
          4. Has a prior history of T-LBL/T-ALL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre- Monash Campus</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Institute</name>
      <address>
        <city>Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital (UZ) Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen - Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lile- Hopital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier- Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes- Hopital Pontchaillou</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussay</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow</name>
      <address>
        <city>Kraków</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.P. Grigoreva Institute of Medical Radiology and Oncology of NAMS of Ukraine&quot;</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson, West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Haematology Clinical Trials Unit</name>
      <address>
        <city>Leicester</city>
        <zip>LEI 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epizyme</keyword>
  <keyword>Tazverik</keyword>
  <keyword>Tazemetostat (EPZ-6438)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Carcinoma, Medullary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

